Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.38 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.37 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854344 | 0.92 | CAPN1 (0.49) | CAPN1 | |
| SCHEMBL22886851 | 0.90 | CAPN1 (0.38) | CAPN1GPR132FTOCTSL | |
| SCHEMBL22886508 | 0.89 | CAPN1 (0.45) | CAPN1GPR132CTSL | |
| SCHEMBL22895963 | 0.86 | CAPN1 (0.42) | CAPN1 | |
| SCHEMBL22896738 | 0.84 | CAPN1 (0.43) | CAPN1GPR132 | |
| SCHEMBL22886426 | 0.84 | FTO (0.42) | CAPN1FTO | |
| SCHEMBL20028424 | 0.82 | PYGL (0.40) | CAPN1MAPK14 | |
| SCHEMBL22896936 | 0.81 | CAPN1 (0.40) | CAPN1 | |
| SCHEMBL21854095 | 0.80 | CAPN1 (0.54) | CAPN1 | |
| SCHEMBL22896819 | 0.80 | CAPN1 (0.47) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885MAPK14 1828/4885GPR132 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.